Laboratory PCR Testing Systems and Regulated Software Practices During the COVID-19 Response

Abstract

The analysis focuses on the testing gap that emerged when public-health authorities needed rapid scale-up of sensitive molecular diagnostics while preserving traceability, safety, and regulatory compliance [1], [2]. The scope spans modular system design, laboratory automation, software configuration management, CI/CD for regulated diagnostic software, and secure data pipelines supporting end-to-end workflows. Key technical contributions highlighted include modular architecture patterns enabling scalable capacity and redundancy, laboratory automation strategies that reduce manual touchpoints, CI/CD approaches adapted to regulated software environments, and secure, auditable data pipelines that align with cybersecurity guidance [3]. Outcomes and implications are presented in anonymized form, emphasizing high-throughput capability improvements, verification and validation (V&V) success, and achievement of regulatory milestones under emergency and routine pathways [2], [4]. The review is relevant to public-health testing networks preparing for future emergencies and to organizations harmonizing software engineering practices with IVDR and FDA EUA expectations [2], [4]. Outcomes and implications are presented in anonymized form, emphasizing high-throughput capability improvements, verification and validation (V&V) success, and achievement of regulatory milestones under emergency and routine pathways [2], [4]. The review is relevant to public-health testing networks preparing for future emergencies and to organizations harmonizing software engineering practices with IVDR and FDA EUA expectations [2], [4].